Home / Peptide Monographs / 5-Amino-1MQ

5-Amino-1MQ: what the human research actually shows

Why I looked into this

5-Amino-1MQ started showing up in biohacker threads as an adjunct to GLP-1 agonists, marketed as a way to boost fat loss by targeting a separate metabolic enzyme. The pitch is built around a 2018 mouse paper that is treated in those threads as if it were a human efficacy study.

The two things that made me want to write this were, first, that the compound is not actually a peptide (it is a small molecule, and the distinction matters for how you evaluate it), and second, that the gap between the preclinical literature and the way the compound is being sold is wider here than for most items on my list.

What 5-Amino-1MQ actually is

5-Amino-1MQ, or 5-amino-1-methylquinolinium iodide, is a small synthetic molecule designed to inhibit the enzyme nicotinamide N-methyltransferase (NNMT). NNMT is expressed at high levels in white adipose tissue in obese animals and humans, where it appears to siphon methyl donors away from sirtuin-dependent pathways and alter the metabolic state of fat cells.

The compound is not a peptide. Peptides are chains of amino acids. 5-Amino-1MQ is a quinolinium salt, closer to a classical small-molecule drug candidate than to anything on the rest of this site. The reason it appears on peptide-style markets is commercial: the same research-use-only suppliers who sell investigational peptides have started listing it alongside them. The reason it appears on this site is that readers are being offered it in those contexts, and the source-safety and evidence-quality questions travel with the product whether or not the “peptide” label is accurate.

What the human research shows

Known safety signals in humans

There is no published human safety data. None. The compound has never been through a Phase 1 dose-range study, never been through formal human toxicology evaluation, and has no pharmacovigilance record. What is known about tolerability comes from rodent studies, which are not a reliable guide to human adverse effects.

The mechanism (NNMT inhibition) touches methyl donor metabolism, which intersects with DNA methylation, one-carbon metabolism, and sirtuin biology. These are pathways where pharmacological intervention is not trivial and where long-term effects in humans would not necessarily be detectable from short-term use. Absence of adverse reports in biohacker forums is not absence of signal, because the surveillance infrastructure to catch a signal does not exist.

FDA and legal status in the US

5-Amino-1MQ has no FDA approval, no IND filing that has surfaced in the public record, and no compounding pathway. It sits in the category of tool compounds used in academic research that have been picked up by research-use-only suppliers and marketed into a consumer-adjacent audience, without the clinical development steps that would produce a legitimate human-use pathway.

The fact that the compound is sold on peptide-style markets does not place it inside the 503A compounding framework that governs some approved peptides. There is no approved reference product, no recognized compendial monograph, and no FDA label. The compound is research-grade material sold through channels that do not carry pharmaceutical-grade accountability.

How to evaluate a source: the safety framework

Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.

The wrinkle for 5-Amino-1MQ specifically

The specific problem with 5-Amino-1MQ is that it sits in a gray zone even by gray-market standards. Unlike an investigational peptide that has at least been through a sponsor-led Phase 2, this compound has not been through any human development. That means there is no trial-grade reference supply to compare gray-market material against. Identity testing at best confirms you have the small molecule on the label; it cannot tell you anything about pharmaceutical-grade purity, sterility, or endotoxin levels if someone is using it in a way that matters for sterility.

Additionally, because 5-Amino-1MQ is a small molecule and not a peptide, the specialized peptide-identity assays some suppliers advertise do not apply in the usual way. A peptide-focused lab is not necessarily the right lab to verify a quinolinium salt.

Cost reality

Research-use-only material labeled 5-Amino-1MQ trades at prices that vary widely across suppliers. There is no pharmacy alternative to compare against, because there is no approved product.

Cost does not track quality in this category. A cheap vial, a premium vial, and a vial from a well-reviewed supplier are all, at the end of the day, research-use-only material that has not been subject to a pharmaceutical-grade release standard.

Questions worth asking any source

• Is this compound correctly identified as a small molecule (5-amino-1-methylquinolinium iodide), not a peptide? What identity test did you use, and does the lab specialize in small-molecule analysis?
• Can you provide a certificate of analysis from an independent, non-peptide-focused lab confirming identity and purity?
• Given that 5-Amino-1MQ has no FDA approval and no IND-level clinical development, what pathway is this material being offered under?
• What is the shelf life, storage specification, and solvent compatibility data for this specific lot?
• What is your policy if a customer has an adverse reaction to this product?

My honest take

Questions to ask your doctor

If you are considering 5-Amino-1MQ, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.

1. I have read about 5-Amino-1MQ as an NNMT inhibitor being marketed alongside peptides. Are you familiar with the target or the literature, and do you see any reason to consider this compound in my situation?
2. Given there are no published human clinical trials, how would you weigh the absence of any human safety record in your clinical judgment?
3. The mechanism touches methyl donor metabolism and one-carbon pathways. Are there baseline labs or existing conditions you would want to consider before anyone used a compound that acts on those pathways?
4. If I had used a research-use-only small molecule with no human data for a short period, what symptoms should I watch for and when should I contact you?
5. Is there any FDA-approved option that addresses whatever outcome I am hoping 5-Amino-1MQ would produce, that we should try or rule out first?
6. Are you aware of any legitimate human clinical trial program for this compound or for NNMT inhibitors generally that I could look into instead?

What to do next

Sources

• Neelakantan H, Vance V, Wang HYL, McHardy SF, Watowich SJ. “Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.” Biochemical Pharmacology. 2018. PMID 29305855.
• Kannt A, Rajagopal S, Kadnur SV, et al. Preclinical work on NNMT inhibition and adipocyte reprogramming. Review-level and primary-literature references available on PubMed.
• ClinicalTrials.gov search: no active or completed human trials for 5-Amino-1MQ under the compound name or obvious synonyms as of April 2026.
• FDA Orange Book and FDA-approved drug databases: no entry.

I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.

Related monographs